Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy

SARS-CoV-2 引起的大流行在 6 个月内已导致全球 43 万人死亡， 总体而言，癌症患者如果被感染，患重病和死亡的风险更高，尽管癌症患者之间存在差异 不同的治疗方案是可能的（例如化疗、免疫疗法、姑息疗法）。癌症患者 从 COVID-19 中康复的人可能需要恢复治疗，包括针对其疾病的免疫治疗 尽管这种感染对免疫系统的影响尚不清楚。该项目将决定 从 COVID-19 中康复的癌症患者是否拥有与癌症功能不同的 NK 细胞 未感染的患者，以及这些表型是否对总体缓解率有影响 这个人口的生存。

The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months which overall place cancer patients at a higher risk of severe illness and death if infected, although differences between distinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patients who have recovered from COVID-19 may need to resume treatment, including immunotherapy for their disease even though the repercussions of this infection on their immune systems are unknown. This project will determine if cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancer patients who were not infected, and whether these phenotypes have an impact on the overall response rate and survival of this population.